NDSN Stock Analysis: Nordson | NASDAQ
Specialty Industrial Machinery | NASDAQ, USA | Market Cap: 16.974m USD | 12M Return: 35.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 113M
EPS Trend: 96.2%
Qual. Beats: -1
Rev. Trend: 95.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Nordson Corporation (NDSN) is a U.S.-based industrial machinery manufacturer that engineers, produces, and markets precision dispensing, application, and control systems for adhesives, coatings, polymers, sealants, biomaterials, and other fluids. Founded in 1909 and headquartered in Westlake, Ohio, the company is a large-cap NASDAQ-listed stock classified within the Industrials sector, specifically the Industrial Machinery & Supplies & Components sub-industry.
The business operates through three reportable segments. Industrial Precision Solutions supplies dispensing, coating, and laminating systems used in disposable products, roll goods, and container/powder coating applications. Medical and Fluid Solutions provides precision dispensers, plastic molded syringes and cartridges, medical tubing, balloons, nitinol devices, and biomaterial delivery components. Advanced Technology Solutions delivers automated dispensing systems, gas plasma treatment equipment, and destructive and non-destructive testing technologies (including bond testers and x-ray/acoustic/optical inspection systems) for the semiconductor and printed circuit board industries.
Nordson reaches customers through a hybrid go-to-market model combining a direct sales force with third-party distributors and sales representatives, a structure typical of diversified industrial equipment makers serving both high-volume manufacturing customers and specialized medical and electronics end markets.
- Semiconductor inspection demand lifts Advanced Technology Solutions order growth
- Disposable hygiene and packaging automation drives Industrial Precision Solutions revenue
- Medical fluid and interventional device sales expand margins through mix shift
| Net Income: 528.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.46 > 1.0 |
| NWC/Revenue: 27.05% < 20% (prev 29.84%; Δ -2.78% < -1%) |
| CFO/TA 0.13 > 3% & CFO 766.5m > Net Income 528.1m |
| Net Debt (1.96b) to EBITDA (910.4m): 2.15 < 3 |
| Current Ratio: 2.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.1m) vs 12m ago -1.62% < -2% |
| Gross Margin: 55.11% > 18% (prev 54.78%; Δ 0.32% > 0.5%) |
| Asset Turnover: 48.29% > 50% (prev 44.61%; Δ 3.67% > 0%) |
| Interest Coverage Ratio: 6.65 > 6 (EBIT TTM 761.6m / Interest Expense TTM 114.6m) |
| A: 0.13 (Total Current Assets 1.28b - Total Current Liabilities 491.9m) / Total Assets 5.96b |
| B: 0.80 (Retained Earnings 4.76b / Total Assets 5.96b) |
| C: 0.13 (EBIT TTM 761.6m / Avg Total Assets 6.01b) |
| D: 1.16 (Book Value of Equity 3.20b / Total Liabilities 2.76b) |
| Altman-Z'' = 5.53 = AAA |
| DSRI: 0.91 (Receivables 606.7m/624.1m, Revenue 2.90b/2.70b) |
| GMI: 0.99 (GM 54.78% / 55.11%) |
| AQI: 1.02 (AQ_t 0.69 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 2.90b / 2.70b) |
| TATA: -0.04 (NI 528.1m - CFO 766.5m) / TA 5.96b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 02, 2026, the stock is trading at USD 301.69 with a total of 534,031 shares traded. Over the past week, the price has changed by -0.16%, over one month by +5.39%, over three months by +10.94% and over the past year by +35.85%.
Current recommended Stop Loss: 283.90 (which is 5.9% or 2.5 ATR below the current price).
Nordson has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy NDSN.
- StrongBuy: 5
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 319.1 | 5.8% |
P/E Trailing = 32.547
P/E Forward = 25.974
P/S = 5.7849
P/B = 5.2438
P/EG = 2.0062
Revenue TTM = 2.90b USD
EBIT TTM = 761.6m USD
EBITDA TTM = 910.4m USD
Long Term Debt = 1.84b USD (from longTermDebt, last quarter)
Short Term Debt = 75.3m USD (from shortTermDebt, last quarter)
Debt = 2.06b USD (from shortLongTermDebtTotal, last quarter) + Leases 87.4m
Net Debt = 1.96b USD (calculated: Debt 2.06b - CCE 102.0m)
Enterprise Value = 18.9b USD (17.0b + Debt 2.06b - CCE 102.0m)
Interest Coverage Ratio = 6.65 (Ebit TTM 761.6m / Interest Expense TTM 114.6m)
EV/FCF = 26.36x (Enterprise Value 18.9b / FCF TTM 718.1m)
FCF Yield = 3.79% (FCF TTM 718.1m / Enterprise Value 18.9b)
FCF Margin = 24.73% (FCF TTM 718.1m / Revenue TTM 2.90b)
Net Margin = 18.19% (Net Income TTM 528.1m / Revenue TTM 2.90b)
Gross Margin = 55.11% ((Revenue TTM 2.90b - Cost of Revenue TTM 1.30b) / Revenue TTM)
Gross Margin QoQ = 54.54% (prev 54.69%)
Tobins Q-Ratio = 3.17 (Enterprise Value 18.9b / Total Assets 5.96b)
Interest Expense / Debt = 5.56% (Interest Expense 114.6m / Debt 2.06b)
Taxrate = 18.46% (119.6m / 647.7m)
NOPAT = 621.0m (EBIT 761.6m * (1 - 18.46%))
Current Ratio = 2.60 (Total Current Assets 1.28b / Total Current Liabilities 491.9m)
Debt / Equity = 0.64 (Debt 2.06b / totalStockholderEquity, last quarter 3.20b)
Debt / EBITDA = 2.15 (Net Debt 1.96b / EBITDA 910.4m)
Debt / FCF = 2.73 (Net Debt 1.96b / FCF TTM 718.1m)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.78% (Net Income 528.1m / Total Assets 5.96b)
RoE = 17.12% (Net Income TTM 528.1m / Total Stockholder Equity 3.08b)
RoCE = 15.48% (EBIT 761.6m / Capital Employed (Equity 3.08b + L.T.Debt 1.84b))
RoIC = 11.40% (NOPAT 621.0m / Invested Capital 5.45b)
WACC = 9.16% (E(17.0b)/V(19.0b) * Re(9.72%) + D(2.06b)/V(19.0b) * Rd(5.56%) * (1-Tc(0.18)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.33 | Cagr: -1.55%
[DCF] Terminal Value 75.40% ; FCFF base≈614.7m ; Y1≈704.7m ; Y5≈1.04b
[DCF] Fair Price = 210.0 (EV 13.7b - Net Debt 1.96b = Equity 11.7b / Shares 55.7m; r=9.16% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.19 | EPS CAGR: 5.59% | SUE: -4.0 | # QB: -1
Revenue Correlation: 94.99 | Revenue CAGR: 3.71% | SUE: 0.51 | # QB: 0
EPS current Quarter (2026-07-31): EPS=3.06 | Chg30d=+0.59% | Revisions=+45% | Analysts=8
EPS current Year (2026-10-31): EPS=11.47 | Chg30d=+0.16% | Revisions=+38% | GrowthEPS=+12.0% | GrowthRev=+6.8%
EPS next Year (2027-10-31): EPS=12.43 | Chg30d=+0.78% | Revisions=+54% | GrowthEPS=+8.4% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +54%